CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that Andrew Hirsch, BIND’s president and chief executive officer, will present at the 2015 Stifel Healthcare Conference on Tuesday, November 17 at 8:45 a.m. ET.
Help employers find you! Check out all the jobs and post your resume.
